MarketInOut Stock Screener Log In | Sign Up
 

Celcuity Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Celcuity Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,208.47 mln
Float40.29 mln
Earnings Date11/18/2026

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

155.92
Transformational upside

Relative Strength

39 / 100
Underperforming

ROE

-374
Deeply negative

ROA

-47.89
Deeply negative

Business Description

Celcuity is a Minneapolis-based clinical-stage company founded in 2011 that develops precision treatments for solid tumors. Its primary focus is Gedatolisib, a drug designed to block key molecular pathways that drive advanced breast cancer and metastatic prostate cancer. The company holds a licensing agreement with Pfizer covering the development and commercialization of this drug candidate.

Key Fundamentals

EPS-4.31
ROE-374
ROIC-1,208
ROA-47.89
Interest Cover-5.95
EBITDA, mln-204
EV / EBITDA-22.10
EV / EBIT-22.08

Quote Details

Last 65.25
Change -0.32 (-0.49%)
Open 65.57
Volume 1,254,444
Turnover 81,852,472
Average Volume 1,706,244

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price155.92
Short Ratio11.35
Short % of Float33.66

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 15.32% 97 / 100   
1 Month -17.79% 20 / 100   
2 Months -25.84% 19 / 100   
6 Months -46.09% 14 / 100   
1 Year -6.84% 39 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog